Search Results for “Alzheimer” – Page 11 – media

Institutions to lead £1.7m-funded network to support people at risk of dementia

The neurodegenerative condition currently affects more than 944,000 people in the UK University College London (UCL) and the University of Exeter are set to co-lead a new national Dementia Network Plus initiative supported by more than £1.7m in funding. The Sustainable Prevention, Innovation and Involvement NETwork (SPIINNET) will help to reduce dementia risk and improve people’s experiences of living with dementia by supporting new projects and engaging with communities. Affecting more than 944,000 people in the UK, dementia is a neurodegenerative condition that affects the ability to remember, think or make decisions in everyday life. The new network will combine researchers from 14 universities with specialist organisations, including King’s College London, the University of Plymouth, Bangor, Cardiff Metropolitan, East Anglia, Northampton, Nottingham, Oxford, Southampton, Stirling, Strathclyde, Sunderland and Worcestershire. SPIINNET aims to utilise existing networks and umbrella organisations to deliver a programme to create connections between the experience, knowledge and ...
- Source: drugdu
- 93
- July 12, 2024
Diagnostic Test Could Detect Elusive Neuro Disorder Using Tiny Drop of Spinal Fluid

Progressive supranuclear palsy (PSP) is a severe neurological disorder classified under frontotemporal dementia (FTD) that impairs cognition, movement, and behavior. Thought to be caused by an accumulation of tau proteins that damage and kill cells, PSP presents symptoms such as poor balance with frequent backward falls and difficulties moving the eyes vertically. Often misdiagnosed as Parkinson’s disease, PSP progresses more rapidly and does not respond to Parkinson’s treatments. Most individuals with PSP pass away approximately seven years after symptoms begin, and frequently, the disease is only identified posthumously during an autopsy. Unlike Alzheimer’s, there are no tau scans, blood tests, or MRIs that can conclusively diagnose PSP, a fact that has hampered the development of treatments. Now, the discovery of a unique pattern of proteins in the spinal fluid of patients could lead to earlier diagnosis and the development of new treatments for PSP. In a study published in Neurology ...
- Source: drugdu
- 103
- July 10, 2024
Study reveals cardiovascular health could be biggest risk factor for dementia

Dementias, including Alzheimer’s disease, are estimated to affect 944,000 people in the UK Researchers from University College London (UCL) have revealed that cardiovascular health could be the biggest risk factor associated with future dementia. Published in the Lancet Public Health, the study was funded by the National Institute for Health and Care Research’s Three Schools’ Dementia Research Programme. Estimated to affect 944,000 people in the UK, dementia is a general term for the impaired ability to remember, think, or make decisions that affects everyday life. The most prevalent dementias include Alzheimer’s disease, vascular dementia, Lewy body dementia and frontotemporal dementia. Researchers analysed and extracted data from 27 papers involving people with dementia worldwide, with data collected between 1947 and 2015 and the latest paper published in 2020. The extracted information from each paper about dementia risk factors was then used to calculate what proportion of dementia cases were attributable to ...
- Source: drugdu
- 104
- July 5, 2024
Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence

As Eli Lilly’s Kisunla (donanemab) enters the Alzheimer’s treatment space, its leading competitor Biogen is undergoing therapy diversification after completing its $1.15bn acquisition of Human Immunology Biosciences (HI-Bio). The deal, which was agreed upon in May this year and includes $650m in milestone payments, sees Biogen bolster its pipeline with US-based HI-Bio’s anti-CD38 monoclonal antibody candidate felzartamab. Biogen’s head of development Priya Singhal said the company is “very excited” about the addition of felzartamab to its rosters in a 2 July press release, adding that Biogen will advance the candidate to Phase III now the transaction is complete. Felzartamab has already demonstrated positive Phase II data in a range of immune-mediated diseases, including IgA nephropathy (IgAN), antibody-mediated rejection (AMR), and primary membranous nephropathy (PMN). The Phase III development plans are for all three diseases, according to Biogen. Felzartamab was originally developed by MorphoSys as a possible competitor to Johnson & ...
- Source: drugdu
- 87
- July 5, 2024
Nanotech to Further Enhance Sensitivity and Accuracy of ELISA Testing for Cancer Screening

The early detection of serious diseases such as cancer or dementia is crucial for effective treatment and improving survival rates. One of the leading methods used for this purpose is the enzyme-linked immunosorbent assay (ELISA), a popular technology in disease screenings. Building upon previous advancements in nanoparticle research, scientists are now working on further enhancing the sensitivity and accuracy of ELISA tests for detecting cancers and other diseases. The promising nanoparticle research being conducted by Associate Professor Xiaohu Xia at the University of Central Florida’s (UCF, Orlando, FL, USA) Department of Chemistry has the potential to increase the accuracy of disease detection by over 300 times compared to current market standards. Supported by a USD 1.3 million grant from the National Institutes of Health, Xia’s four-year project aims to boost the diagnostic performance of ELISA tests by utilizing custom-designed nickel-platinum nanoparticles that attach to specific disease markers like proteins and ...
- Source: drugdu
- 100
- July 3, 2024
UK dementia organisations publish new manifesto ahead of general election

Alzheimer’s Society, Dementia UK, Alzheimer’s Research UK, the UK Dementia Research Institute (UK DRI) and Alzheimer Scotland have collaborated to create a new manifesto for dementia, ahead of the 2024 general election (4 July). The new manifesto, ‘Dementia: a manifesto’, calls on the next UK government to make dementia a key health priority in the UK. Affecting 982,000 people in the UK, dementia is a term for the impaired ability to remember, think or make decisions in day-to-day life. There is currently no cure available and the care and treatment options that currently exist for patients living with the neurodegenerative disease are often disjointed, inaccessible and inadequate. The new manifestos call on the next UK government to better understand how to prevent, reduce and delay dementia; increase access to diagnosis and treatment; help people living with dementia navigate support groups; create a care system that works for everyone; and invest ...
- Source: drugdu
- 106
- June 27, 2024
LucyTx announces additional $12.5m research funding for neurological diseases

Lucy Therapeutics (LucyTx) has announced it has raised $12.5m in additional funding to develop potentially new drugs and advance the company’s research programmes for neurological diseases. The funding, provided by existing investors, Engine Ventures and Safar Partners, with recent participation from the Bill & Melinda Gates Foundation, the Michael J. Fox Foundation and £1.6m from Parkinson’s UK’s Biotech programme, brings the company’s total funding to $36m. The new project aims to develop novel therapies that are based on mitochondrial small-molecule treatments and diagnostic biomarkers for Alzheimer’s (AD) and Parkinson’s disease (PD), as well as continue the development of a novel drug target for Rett syndrome, a rare genetic neurological and developmental disorder that affects brain development. AD and PD are the two most common neurodegenerative diseases worldwide, affecting around 24 million and ten million people, respectively. Using LucyTx’s platform, the team will analyse a variety of disease drivers central to ...
- Source: drugdu
- 77
- June 14, 2024
Eisai to divest rights for two therapies to Kaken

Eisai has signed an agreement for the divestiture of rights for Merislon and Myonal, two of its long-standing products in Japan, to Kaken Pharmaceutical. The transaction is valued at Y3.8bn ($25.10m). Merislon treats vertigo and equilibrium disturbances and Myonal is a muscle relaxant, which patients have used since their respective launches in 1969 and 1983. The agreement stipulates that Eisai will complete the transfer of marketing capabilities by March 2025, followed by manufacturing and marketing approval transfer. The deal will not impact Eisai’s consolidated financial forecast for 31 March 2024. The company stated: “Eisai has determined that divesting rights for these products to Kaken, which has strengths in the products’ disease areas, is the optimal choice to ensure they continue contributing to a greater number of patients.” Eisai will continue to focus on creating and delivering products to target diseases with higher unmet medical needs such as neurology, oncology and ...
- Source: drugdu
- 164
- April 5, 2024
Innovate UK awards ten projects over £6m to develop new clinical tools for dementia

Dementia is estimated to affect 850,000 people in the UK and costs the nation around £23bn a year Innovate UK has awarded ten new projects over £6m in funding to identify, develop and commercialise biomarker clinical tools and technologies for dementia and neurodegeneration. Through Innovate UK’s Small Business Research Initiative, the competition will aid in enhancing clinical trials and precision therapies for patients living with dementia. Estimated to affect 850,000 people in the UK, dementia is a general term for the impaired ability to remember, think or make decisions, which is economically responsible to cost £23bn a year. Alzheimer’s disease, the most common form of dementia, affects one in 14 people over the age of 65 and one in six people over the age of 80. In alignment with the Dame Barbara Windsor Dementia Mission, a government-led effort to develop new precision dementia therapies and solutions in the UK, the ...
- Source: drugdu
- 139
- March 26, 2024
New study reveals neurological conditions as leading cause of ill health worldwide

In 2021, neurological conditions, including Alzheimer’s disease, affected approximately 3.4 billion people globally In a new study funded by the Bill & Melinda Gates Foundation, results published in the Lancet Neurology have determined that neurological conditions are currently the leading cause of ill health worldwide. Results showed that the biggest contributors to neurological health loss globally were stroke, neonatal encephalopathy, migraine, Alzheimer’s disease and other dementias, and diabetic neuropathy. Affecting 3.4 billion people globally in 2021, neurological conditions are any conditions that affect the brain, spinal cord and nerves, which can affect anyone at any age. The study revealed that the number of people globally living with or dying from neurological conditions has drastically risen in the past three decades, partially due to ageing societies. Worldwide, the analysis suggests that the total amount of disability, illness and premature death caused by neurological conditions increased by 18% between 1990 and 2021. ...
- Source: drugdu
- 126
- March 22, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.